Vistagen Therapeutics (VTGN) Return on Invested Capital (2012 - 2021)
Vistagen Therapeutics (VTGN) posted Return on Invested Capital of 1.17% for Q3 2021, down 244.31% sequentially from 0.34% in Q2 2021, and down 97.0% YoY from 38.91% in Q3 2020.
Vistagen Therapeutics (VTGN) Return on Invested Capital (2012 - 2021) Analysis & Trends
Vistagen Therapeutics has reported Return on Invested Capital for 9 years, with the latest figure at 1.17% in Q3 2021.
- Quarterly Return on Invested Capital fell 97.0% year-over-year to 1.17% in Q3 2021, while the trailing twelve-month figure through Sep 2021 was 1.17% (down 97.0% YoY) and the FY2020 annual result came in at 3.66%, up 76.0% from the prior year.
- Return on Invested Capital declined to 1.17% in Q3 2021 per VTGN's latest filing, from 0.34% in the prior quarter.
- Over five years, Return on Invested Capital peaked at 0.16% in Q4 2020 and troughed at 1.21% in Q1 2017.
- A 5-year average of 0.49% and a median of 0.43% in 2018 frame the typical range for Return on Invested Capital.
- The sharpest annual moves came in 2017 and 2021: Return on Invested Capital jumped 352 bps in 2017, then sank 97 bps in 2021.
- Over 5 years, Return on Invested Capital stood at 0.35% in 2017, then sank by 66 bps to 0.58% in 2018, then gained by 23 bps to 0.44% in 2019, then jumped by 64 bps to 0.16% in 2020, then plunged by 619 bps to 1.17% in 2021.
- According to Business Quant data, Return on Invested Capital over the past three periods registered 1.17%, 0.34%, and 0.2% for Q3 2021, Q2 2021, and Q1 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.04% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -0.17% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | -1.17% |
| Jun 30, 2021 | -0.34% |
| Mar 31, 2021 | -0.20% |
| Dec 31, 2020 | -0.16% |
| Sep 30, 2020 | -0.19% |
| Jun 30, 2020 | -0.28% |
| Mar 31, 2020 | -0.39% |
| Dec 31, 2019 | -0.44% |
| Sep 30, 2019 | -0.50% |
| Jun 30, 2019 | -0.61% |
| Mar 31, 2019 | -0.61% |
| Dec 31, 2018 | -0.58% |
| Sep 30, 2018 | -0.48% |
| Jun 30, 2018 | -0.43% |
| Mar 31, 2018 | -0.39% |
| Dec 31, 2017 | -0.35% |
| Sep 30, 2017 | -0.40% |
| Jun 30, 2017 | -0.61% |
| Mar 31, 2017 | -1.21% |
| Dec 31, 2016 | -2.63% |